Rob P. Davis

Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation

Huw D. Lewis, John Liddle, Jim Coote et al. · Nature Chemical Biology · 2015 · 760 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +2

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins

Robert J. Watson, Paul Bamborough, Heather Barnett et al. · Journal of Medicinal Chemistry · 2020 · 87 citations · Full text

Medicine, Oncology, Pharmacology +9

Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor

John Liddle, Francis Atkinson, Michael D. Barker et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 54 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors

Simon C. C. Lucas, Stephen J. Atkinson, Chun‐wa Chung et al. · Journal of Medicinal Chemistry · 2021 · 25 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease

Michael D. Barker, John Liddle, Francis Atkinson et al. · Bioorganic & Medicinal Chemistry Letters · 2018 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16